3 results
Primary objective: to evaluate safety of everolimus in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer that is refractory to NSAIs.Secondary objective: to evaluate adverse events grade 3 and 4 in theā¦
This study aims to validate NI-fECG monitoring as an accurate and reliable monitoring technique for FHR, MHR and UA surveillance during labour. The aim of this validation is to work towards clinical implementation of NI-fECG monitoring.
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.